HEALTH PROFESSIONAL · SOURCE READING

Good Prognosis

Source: Testicular Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 16, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Testicular Cancer

Nonseminoma:

Testis/retroperitoneal primary, and

No nonpulmonary visceral metastases, and

Good markers–all of:

Alpha-fetoprotein (AFP) less than 1,000 ng/mL, and

Good markers–all of:

Beta-human chorionic gonadotropin (beta-hCG) less than 5,000 IU/mL (1,000 ng/mL), and

Good markers–all of:

Lactate dehydrogenase (LDH) less than 1.5 × the upper limit of normal

A total of 56% to 61% of nonseminomas are good prognosis. The 5-year progression-free survival (PFS) rate is 89%; the 5-year survival rate is 92%–94%.

Seminoma:

Any primary site, and

No nonpulmonary visceral metastases, and

Normal AFP, any beta-hCG, any LDH

A total of 90% of seminomas are good prognosis. The 5-year PFS rate is 82%; the 5-year survival rate is 86%.

Preserved source evidence · Not medical advice